Colorectal Cancer Risk between Mendelian and Non-Mendelian Inheritance

Abstract

Hereditary colorectal cancer has been an area of focus for research and public health practitioners due to our ability to quantify risk and then act based on such results by enrolling patients in surveillance programs. The wide access to genetic testing and whole-genome sequencing has resulted in identifying many low/moderate penetrance genes. Above all, our understanding of the family component of colorectal cancer has been improving. Polygenic scores are becoming part of the risk assessment for many cancers, and the data about polygenic risk scores for colorectal cancer is promising. The challenge is determining how we incorporate this data in clinical care.

Keywords

cancer - inherited - polygenic - penetrance - Mendelian

Publication History

Article published online:
31 July 2023

• References

• 1 American Cancer Society. Cancer Facts & Figures 2023. Atlanta, GA: American Cancer Society; 2023
• 2 Armelao F, de Pretis G. Familial colorectal cancer: a review. World J Gastroenterol 2014; 20 (28) 9292-9298
• 3 Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 2006; 42 (02) 216-227
• 4 Møller P, Seppälä TT, Bernstein I. et al; Mallorca Group. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut 2018; 67 (07) 1306-1316
• 5 Huyghe JR, Bien SA, Harrison TA. et al. Discovery of common and rare genetic risk variants for colorectal cancer. Nat Genet 2019; 51 (01) 76-87
• 6 Jenkins MA, Buchanan DD, Lai J. et al. Assessment of a polygenic risk score for colorectal cancer to predict risk of Lynch syndrome colorectal cancer. JNCI Cancer Spectr 2021; 5 (02) pkab022
• 7 International Mismatch Repair Consortium. Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. Lancet Oncol 2021; 22 (07) 1014-1022
• 8 Snyder C, Hampel H. Hereditary colorectal cancer syndromes. Semin Oncol Nurs 2019; 35 (01) 58-78
• 9 Law PJ, Timofeeva M, Fernandez-Rozadilla C. et al; PRACTICAL consortium. Association analyses identify 31 new risk loci for colorectal cancer susceptibility. Nat Commun 2019; 10 (01) 2154
• 10 Stoffel EM, Koeppe E, Everett J. et al. Germline genetic features of young individuals with colorectal cancer. Gastroenterology 2018; 154 (04) 897-905.e1
• 11 Schubert SA, Morreau H, de Miranda NFCC, van Wezel T. The missing heritability of familial colorectal cancer. Mutagenesis 2020; 35 (03) 221-231
• 12 Chubb D, Broderick P, Dobbins SE. et al. Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer. Nat Commun 2016; 7: 11883
• 13 Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331 (25) 1669-1674
• 14 Yurgelun MB, Kulke MH, Fuchs CS. et al. Cancer susceptibility gene mutations in individuals with colorectal cancer. J Clin Oncol 2017; 35 (10) 1086-1095
• 15 Davidson KW, Barry MJ, Mangione CM. et al; US Preventive Services Task Force. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA 2021; 325 (19) 1965-1977
• 16 Lewis CM, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med 2020; 12 (01) 44
• 17 Choi SW, Mak TS, O'Reilly PF. Tutorial: a guide to performing polygenic risk score analyses. Nat Protoc 2020; 15 (09) 2759-2772
• 18 Polygenic Risk Score Task Force of the International Common Disease Alliance. Responsible use of polygenic risk scores in the clinic: potential benefits, risks and gaps. Nat Med 2021; 27 (11) 1876-1884
• 19 Chatterjee N, Shi J, García-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet 2016; 17 (07) 392-406
• 20 Lewis ACF, Green RC. Polygenic risk scores in the clinic: new perspectives needed on familiar ethical issues. Genome Med 2021; 13 (01) 14
• 21 Lambert SA, Abraham G, Inouye M. Towards clinical utility of polygenic risk scores. Hum Mol Genet 2019; 28 (R2): R133-R142
• 22 Torkamani A, Wineinger NE, Topol EJ. The personal and clinical utility of polygenic risk scores. Nat Rev Genet 2018; 19 (09) 581-590
• 23 Ma H, Brosens LAA, Offerhaus GJA, Giardiello FM, de Leng WWJ, Montgomery EA. Pathology and genetics of hereditary colorectal cancer. Pathology 2018; 50 (01) 49-59
• 24 Kanth P, Grimmett J, Champine M, Burt R, Samadder NJ. Hereditary colorectal polyposis and cancer syndromes: a primer on diagnosis and management. Am J Gastroenterol 2017; 112 (10) 1509-1525
• 25 Bonadona V, Bonaïti B, Olschwang S. et al; French Cancer Genetics Network. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA 2011; 305 (22) 2304-2310
• 26 Thomas M, Sakoda LC, Hoffmeister M. et al. Genome-wide modeling of polygenic risk score in colorectal cancer risk. Am J Hum Genet 2020; 107 (03) 432-444
• 27 Ryan NAJ, Morris J, Green K. et al. Association of mismatch repair mutation with age at cancer onset in Lynch syndrome: implications for stratified surveillance strategies. JAMA Oncol 2017; 3 (12) 1702-1706
• 28 Senter L, Clendenning M, Sotamaa K. et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology 2008; 135 (02) 419-428
• 29 Ten Broeke SW, van der Klift HM, Tops CMJ. et al. Cancer risks for PMS2-associated Lynch syndrome. J Clin Oncol 2018; 36 (29) 2961-2968
• 30 Jenkins MA, Buchanan DD, Lai J. et al. Assessment of a polygenic risk score for colorectal cancer to predict risk of Lynch Syndrome colorectal cancer. JNCI Cancer Spectr 2021; 5 (02) pkab022
• 31 Fishel R, Lescoe MK, Rao MR. et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 1994; 77 (01) 1, 166
• 32 Boland CR, Lynch HT. The history of Lynch syndrome. Fam Cancer 2013; 12 (02) 145-157
• 33 Hassanin E, Spier I, Bobbili DR. et al. Clinically relevant combined effect of polygenic background, rare pathogenic germline variants, and family history on colorectal cancer incidence. BMC Med Genomics 2023;16(42)
• 34 Fahed AC, Wang M, Homburger JR. et al. Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions. Nat Commun 2020; 11 (01) 3635
• 35 Swift M, Morrell D, Cromartie E, Chamberlin AR, Skolnick MH, Bishop DT. The incidence and gene frequency of ataxia-telangiectasia in the United States. Am J Hum Genet 1986; 39 (05) 573-583
• 36 Meijers-Heijboer H, van den Ouweland A, Klijn J. et al; CHEK2-Breast Cancer Consortium. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet 2002; 31 (01) 55-59
• 37 Bülow S, Berk T, Neale K. The history of familial adenomatous polyposis. Fam Cancer 2006; 5 (03) 213-220
• 38 Roos VH, Mangas-Sanjuan C, Rodriguez-Girondo M. et al. Effects of family history on relative and absolute risks for colorectal cancer: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2019; 17 (13) 2657-2667.e9
• 39 Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology 2010; 138 (06) 2044-2058
• 40 Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96 (10) 2992-3003
• 41 Frampton MJ, Law P, Litchfield K. et al. Implications of polygenic risk for personalised colorectal cancer screening. Ann Oncol 2016; 27 (03) 429-434